LCT 0.047 Last updated EOD 18th January 2019
The following fact sheets provide a summary of our current business and research pipeline.
Living Cell Technologies was initially formed to commercialise research into treatments for type 1 diabetes. Today we are a recognised world leader in pioneering cell transplant therapeutics.
Established by Professor Bob Elliott and David Collinson, the company (then known as Diatranz) began hiring in 1999. In 2003 we became Living Cell Technologies, listing on the ASX in 2004.
Initially Living Cell Technologies focused all resources on developing DIABECELL® as an effective treatment for unstable type 1 diabetes. In 2011, following successful Phase I trials of DIABECELL, Living Cell Technologies formed a partnership with Otsuka Pharmaceutical Factory, Inc. (Otsuka) establishing the 50:50 New Zealand joint venture company Diatranz Otsuka Limited (DOL). In 2014 DOL licensed Otsuka to further develop the product in USA and Japan. In January 2018 LCT sold its shares in DOL and we are in discussion with Otsuka Pharmaceutical Factory regarding an exclusive licence to use DIABECELL in Australia, Argentina and New Zealand once it is approved for use.
Today Living Cell Technologies is focused on developing cell therapies to treat neurological disorders.
When Bob Elliott was Professor of Child Health Research at The University of Auckland a colleague asserted that Alzheimer’s disease could be described as diabetes of the brain, meaning that some hormones made in the brain are missing in people with Alzheimer’s. This concept fascinated Bob. A search of the literature found that the choroid plexus in the brain produces neurotrophins, which are found in levels below normal in patients with Alzheimer’s. In a meeting with a neurological group from Yale University it was suggested that Parkinson’s disease would be a less difficult target than Alzheimer’s.
In 2001 Dr Stephen Skinner was recruited to carry out a small animal study with NTCELL. This was later followed up with a monkey study which indicated that NTCELL was safe and efficacious in an animal model of Parkinson’s disease.
In 2011 we announced a second product line based on transplanting choroid plexus brain cells. NTCELL® has the potential to treat neurodegenerative diseases, including Parkinson’s.
In 2013 a four patient Phase I/IIa clinical trial of NTCELL in Parkinson’s disease commenced.
A Phase IIb clinical trial of NTCELL is currently underway in Auckland, New Zealand.